Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2024-11-14 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 8-K
Regulatory Filings Classification · 95% confidence The document is an announcement by Zai Lab Limited regarding the filing of a Form 8-K with the U.S. SEC. It specifically states that the Form 8-K supplements and updates risk factors disclosures previously included in the company's Annual Report on Form 10-K for the year ended December 31, 2023. The document includes the full text of the Form 8-K, including updated risk factors disclosures as Exhibit 99.1. The document is about a current report (Form 8-K) filed with the SEC, which is a regulatory filing used to report unscheduled material events or corporate changes. It is not the Annual Report (10-K) itself, nor is it a brief announcement of a report publication. The document contains substantive disclosure updates and is a standalone regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-11-14 English
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q
Interim / Quarterly Report Classification · 100% confidence The document is titled 'OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q' and references the filing of a Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, with the U.S. Securities and Exchange Commission (SEC). It includes detailed financial statements, management discussion and analysis, risk factors, and other comprehensive quarterly report content. The document is approximately 15,000 characters long, indicating it is the full report rather than a brief announcement or certification. The presence of unaudited condensed consolidated financial statements and management's discussion confirms it is a quarterly financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-11-12 English
UNAUDITED RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND CORPORATE UPDATES
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement of unaudited financial results for the three and nine months ended September 30, 2024, including comprehensive financial data such as product revenues, expenses, net loss, and cash position. It also includes corporate updates, pipeline progress, and anticipated milestones. The presence of detailed financial figures and analysis for a quarterly period indicates this is a quarterly financial report. The document is not merely an announcement of a report or a certification, but contains substantive financial data and management commentary. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-11-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report for movements in securities of Zai Lab Limited, specifically covering authorized share capital, issued shares, share options, and other share-related movements for the month ended 31 October 2024. It includes confirmations pursuant to Hong Kong Stock Exchange listing rules about compliance and authorization of share issuances. The document is structured as a regulatory submission to the Hong Kong Exchanges and Clearing Limited and focuses on share capital changes and share option schemes. It does not contain financial performance data, earnings, management discussion, or audit information. It is not an announcement of a report but a detailed regulatory filing about share capital movements and confirmations. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-11-06 English
NOTICE OF AUDIT COMMITTEE ACTION AND DATE OF PUBLICATION OF THIRD QUARTER 2024 RESULTS ANNOUNCEMENT
Report Publication Announcement Classification · 95% confidence The document is an announcement from Zai Lab Limited regarding the upcoming Audit Committee meeting to approve the unaudited quarterly results for the three and nine months ended September 30, 2024. It states that the results will be published on November 12, 2024, and that a live earnings teleconference call will be held to discuss these results. The document itself does not contain the financial results or detailed financial data but rather announces the date of publication and the call. The document length is 3073 characters, which is relatively short and fits the pattern of an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement about the publication of a report and an upcoming earnings call, not the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2024-10-31 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Regulatory Filings Classification · 95% confidence The document is an announcement from Zai Lab Limited regarding the grant of share options and restricted share units under the 2024 Equity Incentive Plan. It details the number of options and restricted share units granted, the vesting periods, exercise prices, and other terms related to employee equity compensation. The announcement references compliance with Listing Rules and provides definitions related to the equity plan. There is no indication that this is a full financial report, audit report, or earnings release. Instead, it is a regulatory announcement about share-based compensation grants to employees, which fits the category of a Regulatory Filing (RNS) as it does not fall under more specific categories like Director's Dealing or Share Issue/Capital Change (since it is about option grants, not actual share issuance). The document is longer than 5,000 characters and contains detailed information about the grants, but it is not a financial report or presentation. Therefore, the best classification is Regulatory Filings (RNS).
2024-10-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.